Janssen Search
Search results
Global Public Health
Global Public Health Global Public Health Nelly Velez, The World Among Us About Our Global Public Health Initiative Global Public Health Research Increasing Sustainable Access to Medicines Our Partnerships Fighting Multi-Drug Resistant Tuberculosis ...
Recognizing World Psoriasis Day
Recognizing World Psoriasis Day On October 29, World Psoriasis Day, we at Janssen recognize the debilitating effects diseases like psoriasis and psoriatic arthritis have on patients and their loved ones. That’s why, for more than a decade, our team has ...
Immune Therapy
Immune Therapy “Interventions that harness the power of the immune system have shown exciting potential in the treatment of cancer.” Joseph Erhardt, Ph.D. Vice President, Oncology Scientific Partnership Strategy One of the most significant advancements in ...
Leveraging a Pathway Approach to help Restore Balance to the Immune System
Leveraging a Pathway Approach to Help Restore Balance to the Immune System Janssen is committed to leveraging a pathway approach to help restore balance to the immune system, which in people living with autoimmune diseases responds by attacking healthy ...
Science of Immorbidity
2 nd International Symposium, 12 October 2017: The Science of Immorbidity- New Approaches to Prevention in Creating a World Without Disease About the Symposium The word immorbidity describes a state where a person is able to evade the diseases that ...
Commercialization of Cardiovascular Treatment
Commercialization Bringing transformational care and treatment options to patients. At Janssen, our worldwide commercial entities are working to market and ensure access to medicines in more than 175 countries. We have success rates in securing approvals, ...
Nick Pineda
In his role of Chief of Staff of the Janssen Human Microbiome Institute (JHMI), Nick is responsible for the execution and operationalization of the JHMI strategy. This includes implementing key systems and processes needed to establish a growth portfolio ...
Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH
Nov 29, 2023 United States Data highlights strength of multi-target, multi-platform multiple myeloma portfolio and continued innovation in B-cell malignancies to transform patient outcomes RARITAN, N.J., November 29, 2023 – Johnson & Johnson ...
Living with PAH
Living with Pulmonary Arterial Hypertension (PAH) PAH is a rare, progressive disease that currently has no cure. The immediate goal is to prolong survival whilst improving the quality of life for those living with the disease. To achieve these goals, ...
Tackling the Stigma Around Plaque Psoriasis
Tackling the Stigma of Plaque Psoriasis Growing up with atopic dermatitis and severe plaque psoriasis, Howard Chang frequently encountered negativity because of his skin. In addition to managing the discomfort and painful symptoms of plaque psoriasis, ...